Goldman Sachs
DNA icon

Goldman Sachs’s Ginkgo Bioworks DNA Stock Holding History

Goldman Sachs’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.02M Sell
607,376
-322,486
-35% -$2.7M ﹤0.01% 3714
2026
Q1 		$5.7M Buy
929,862
+10,553
+1% +$87.8K ﹤0.01% 3572
2025
Q4 		$7.64M Buy
919,309
+94,021
+11% +$1.01M ﹤0.01% 3343
2025
Q3 		$12M Sell
825,288
-317,511
-28% -$3.8M ﹤0.01% 2781
2025
Q2 		$12.9M Buy
1,142,799
+456,032
+66% +$3.53M ﹤0.01% 2534
2025
Q1 		$3.91M Buy
686,767
+139,126
+25% +$1.42M ﹤0.01% 3593
2024
Q4 		$5.38M Buy
547,641
+180,601
+49% +$1.55M ﹤0.01% 3383
2024
Q3 		$2.99M Buy
367,040
+227,522
+163% +$2.28M ﹤0.01% 3789
2024
Q2 		$1.87M Buy
139,518
+85,410
+158% +$2.55M ﹤0.01% 3969
2024
Q1 		$2.51M Buy
54,108
+36,506
+207% +$1.89M ﹤0.01% 3695
2023
Q4 		$1.19M Sell
17,602
-7,535
-30% -$461K ﹤0.01% 4284
2023
Q3 		$1.82M Buy
25,137
+14,057
+127% +$1.12M ﹤0.01% 3836
2023
Q2 		$824K Buy
11,080
+5,357
+94% +$317K ﹤0.01% 4474
2023
Q1 		$304K Sell
5,723
-31,594
-85% -$2M ﹤0.01% 5098
2022
Q4 		$2.52M Buy
37,317
+10,115
+37% +$930K ﹤0.01% 3751
2022
Q3 		$3.4M Sell
27,202
-78,904
-74% -$9.4M ﹤0.01% 3498
2022
Q2 		$10.1M Buy
106,106
+98,109
+1,227% +$12M ﹤0.01% 2504
2022
Q1 		$1.29M Buy
+7,997
New +$1.56M ﹤0.01% 4623

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Goldman Sachs's DNA Position: Q2 2026 in Review

Goldman Sachs reduced its Ginkgo Bioworks (DNA) stake by 35% in Q2 2026, selling an estimated $2.7M and leaving 607,376 shares worth $6.02M. The position accounts for ﹤0.01% of the portfolio, ranked #3714.

Goldman Sachs first reported a position in DNA in Q1 2022 and has held it in 18 quarters since. The position peaked at $12.9M in Q2 2025. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Goldman Sachs held 607,376 shares of Ginkgo Bioworks worth $6.02M as of Q2 2026.
  • Goldman Sachs sold 322,486 Ginkgo Bioworks shares in Q2 2026, an estimated $2.7M.
  • Ginkgo Bioworks made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3714 holding.
  • Goldman Sachs first reported a position in Ginkgo Bioworks in Q1 2022 and has held it in 18 quarters since.
  • Goldman Sachs's Ginkgo Bioworks position peaked at $12.9M in Q2 2025.
  • 184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.